Publications
Detailed Information
Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson¿s disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yun, Ji Young | - |
dc.contributor.author | Kim, Han-Joon | - |
dc.contributor.author | Lee, Jee-Young | - |
dc.contributor.author | Kim, Young Eun | - |
dc.contributor.author | Kim, Ji Seon | - |
dc.contributor.author | Kim, Jong-Min | - |
dc.contributor.author | Jeon, Beom S | - |
dc.date.accessioned | 2013-10-02T04:35:09Z | - |
dc.date.available | 2013-10-02T04:35:09Z | - |
dc.date.issued | 2013-09-02 | - |
dc.identifier.citation | BMC Neurology Vol.13 No.113, pp.1-7 | ko_KR |
dc.identifier.issn | 1471-2377 | - |
dc.identifier.uri | https://hdl.handle.net/10371/83494 | - |
dc.identifier.uri | http://www.biomedcentral.com/1471-2377/13/113 | - |
dc.description | Trial registration : This study is registered with ClinicalTrials.gov, number NCT00986245. | ko_KR |
dc.description.abstract | Background : Ropinirole prolonged release (RPR) is a once-daily formulation. However, there may be individual pharmacokinetic differences so that multiple dosing may be preferred in some individuals. This study compares once-daily and twice-daily RPR in patients with Parkinsons disease.
Methods : This study was an open-label crossover study. We enrolled Parkinsons disease patients on dopamine agonist therapy with unsatisfactory control such as motor fluctuation, dyskinesia and sleep-related problems. Agonists were switched into equivalent dose of RPR. Subjects were consecutively enrolled into either once-daily first or twice-daily first groups, and received the same amount of RPR in a single and two divided dosing for 8weeks respectively in a crossover manner without a washout period. The primary outcome was a questionnaire of the preference completed by patients in the last visit. The secondary outcome measures included the Unified Parkinsons Disease Rating Scale part 3 (mUPDRS), Hoehn and Yahr stage (H&Y); sleep questionnaire including overall quality of sleep, nocturnal off symptoms and early morning symptoms; Epworth Sleep Scale (ESS); compliances and patient global impression (PGI). Results : A total of 82 patients were enrolled and 61 completed the study. 31 patients preferred twice-daily regimen, 17 preferred the once-daily regimen, and 13 had no preference. Their mean mUPDRS, H&Y, ESS, sleep quality, compliance and adverse events were not statistically different in both regimens. PGI-improvement on wearing off defined was better in twice-daily dosing regimen. Conclusions : RPR is a once-daily formulation, but multiple dosing was preferred in many patients. Multiple dosing of RPR might be a therapeutic option if once-daily dosing is unsatisfactory. | ko_KR |
dc.description.sponsorship | This study was supported by a grant of the Korea Health technology R&D Project, Ministry of Health & Welfare, Republic of Korea. (A101273, BSJ). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central Ltd. | ko_KR |
dc.subject | Parkinson’s disease | ko_KR |
dc.subject | Motor control | ko_KR |
dc.subject | Movement disorders | ko_KR |
dc.subject | Dopamine agonist | ko_KR |
dc.title | Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson¿s disease | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 윤지영 | - |
dc.contributor.AlternativeAuthor | 김한준 | - |
dc.contributor.AlternativeAuthor | 이재영 | - |
dc.contributor.AlternativeAuthor | 김영은 | - |
dc.contributor.AlternativeAuthor | 김지선 | - |
dc.contributor.AlternativeAuthor | 김종민 | - |
dc.identifier.doi | 10.1186/1471-2377-13-113 | - |
dc.citation.journaltitle | BMC Neurology | - |
dc.language.rfc3066 | en | - |
dc.description.version | Peer Reviewed | - |
dc.rights.holder | Ji Yun et al.; licensee BioMed Central Ltd. | - |
dc.date.updated | 2013-10-01T19:30:57Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.